Literature DB >> 3720178

Fibrotic process and drug metabolism in alcoholic liver disease.

E A Sotaniemi, O Niemelä, L Risteli, F Stenbäck, R O Pelkonen, J T Lahtela, J Risteli.   

Abstract

The effect of fibrosis on drug metabolism in alcoholic liver disease was evaluated in a comparison of the concentrations of serum aminoterminal propeptide of type III procollagen and basement membrane (BM; 7S domain of type IV collagen and laminin) antigens with in vitro (cytochrome P-450) and in vivo (antipyrine) drug metabolism in 67 alcoholics classified by liver histology. Alcoholics with intact or fatty liver had rapid or normal drug metabolism and normal collagen metabolism. Alcoholics with a fatty liver plus fibrosis or active cirrhosis had reduced drug metabolism and elevated levels of serum markers for collagen and BM metabolism. Alcoholics with inactive cirrhosis who had received therapy with enzyme inducers had a tendency toward normal drug and collagen metabolism parameters. Antipyrine metabolism, but not P-450 content, was related to the levels of serum type III collagen and BM markers. The fibrotic process, especially BM formation, creates a mechanical barrier that may prevent contact between blood and hepatocytes, thus delaying substrate availability.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720178     DOI: 10.1038/clpt.1986.138

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity.

Authors:  H Kraul; J Truckenbrodt; A Huster; R Töpfer; A Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

3.  The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.

Authors:  J Hasselström; S Eriksson; A Persson; A Rane; J O Svensson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

Review 4.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

5.  Antipyrine clearance and metabolite formation in primary biliary cirrhosis.

Authors:  F Jorquera; M Almar; A Linares; J L Olcóz; L Rodrigo; J González-Gallego
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

6.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.